SCHEMBL1719129

SCHEMBL1719129

NC(=O)c1ccc(Cc2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 2/20 1.00
PLA2G10 O15496 1/20 1.00
LMNA P02545 1/20 0.64
PARP1 P09874 2/20 0.62
POLB P06746 1/20 0.62
CYP3A4 P08684 1/20 0.62
MAPT P10636 1/20 0.62
TSHR P16473 1/20 0.62
CYP2C19 P33261 1/20 0.62
RECQL P46063 1/20 0.62
BLM P54132 1/20 0.62
PMP22 Q01453 1/20 0.62
HSD17B10 Q99714 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
PARP10 Q53GL7 5/20 0.59
CYP17A1 P05093 1/20 0.59
CALM1 P0DP23 1/20 0.52
SLC22A2 O15244 1/20 0.52
SRD5A2 P31213 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28396819 0.96 PLA2G2A (0.92) PLA2G2APLA2G10LMNAPARP1POLB
SCHEMBL7134591 0.91 PLA2G10 (0.83) PLA2G2APLA2G10LMNAPARP1POLB
SCHEMBL28837994 0.87 PLA2G10 (0.77) PLA2G2APLA2G10PARP1POLBCYP3A4
Diphenylmethane SCHEMBL18604552 0.84 PLA2G10 (0.71) PLA2G2APLA2G10LMNAPARP1POLB
Diphenylmethane SCHEMBL28144267 0.84 PLA2G10 (0.71) PLA2G2APLA2G10LMNAPARP1POLB
Diphenylmethane SCHEMBL8743340 0.84 PLA2G10 (0.71) PLA2G2APLA2G10LMNAPARP1POLB
Diphenylmethane SCHEMBL10451543 0.84 PLA2G10 (0.71) PLA2G2APLA2G10LMNAPARP1POLB
SCHEMBL502598 0.82 SRD5A2 (0.71) PLA2G2APLA2G10LMNATSHRHSD17B10
SCHEMBL1247035 0.82 PLA2G10 (0.69) PLA2G2APLA2G10LMNATSHRTDP1
SCHEMBL5482345 0.82 SRD5A2 (0.71) PLA2G2APLA2G10LMNATSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506196-B1 PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2012-01-18 EP claimed
US-20090215783-A1 COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION CHOONGWAE PHARMA CORPORATION (KR) 2009-08-27 US claimed
EP-2029142-A1 COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION Choongwae Pharma Corporation (KR) 2009-03-04 EP claimed
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US claimed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP claimed
WO-2007139346-A1 COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION CHOONGWAE PHARMA CORPORATION (KR) 2007-12-06 WO claimed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO claimed
US-20040002521-A1 Cyclopropanecarboxylic acid amide compound and pharmaceutical use thereof AJINOMOTO CO. INC 2004-01-01 US claimed
US-20250367649-A1 PHOTOCATALYSTS, PREPARATION AND USE THEREOF THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) 2025-12-04 US disclosed
US-12383531-B2 PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury OPHIREX, INC. (US) 2025-08-12 US disclosed
US-20250120949-A1 USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS OPHIREX, INC. (US) 2025-04-17 US disclosed
CN-114479404-B Thermoplastic resin composition and molded article produced therefrom 乐天化学株式会社 2024-08-23 CN disclosed
CN-114466894-B Thermoplastic resin composition and molded article produced therefrom 乐天化学株式会社 2024-05-31 CN disclosed
EP-3448378-B1 PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY OPHIREX INC (US) 2024-04-17 EP disclosed
EP-1326853-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS Warner-Lambert Company LLC (US) 2003-07-16 EP disclosed
CN-1429251-A Red phosphorus fire retardant for epoxy, red phosphorus fire retardant composition for epoxy, their mfg. method, epoxy composition for semiconductor sealing materials NIPPON CHEMICAL INDUSTRY CO LT (JP) 2003-07-09 CN disclosed
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT COMPANY 2003-03-06 US disclosed
WO-2002028847-A1 NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-04-11 WO disclosed
EP-1043991-A1 TREATMENT FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 2000-10-18 EP disclosed
WO-1999025340-A1 TREATMENT FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1999-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12383531-B2 PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury PLA2G4A, PLA2G12A, PLA2G6 PLA2G2A 4/4885PLA2G10 11/4885LMNA 2567/4885
US-20090215783-A1 COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION MYLK2, TNNC1, MYH2 PLA2G2A 2371/4885PLA2G10 2317/4885LMNA 194/4885
US-20250367649-A1 PHOTOCATALYSTS, PREPARATION AND USE THEREOF PPOX, AOX1, CYP3A7 PLA2G2A 3505/4885PLA2G10 4097/4885LMNA 3737/4885
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them HDAC1, HDAC8, HDAC9 PLA2G2A 4822/4885PLA2G10 4856/4885LMNA 1681/4885
US-20040002521-A1 Cyclopropanecarboxylic acid amide compound and pharmaceutical use thereof NFKBIA, IKBKB, CHUK PLA2G2A 2635/4885PLA2G10 2713/4885LMNA 3431/4885
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors PDE3A, PDE3B, PDE7A PLA2G2A 2672/4885PLA2G10 2492/4885LMNA 3287/4885
US-20250120949-A1 USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS PLA2G12A, PLA2G2D, PLAAT2 PLA2G2A 12/4885PLA2G10 18/4885LMNA 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.